Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Featured Research

Can we predict who is at risk of facing cognitive issues in PD and address them earlier? These are the questions being pursued by Dr. Goldman of the PDF Research Center at Rush University Medical Center.

Learn More

PDF Grant Programs

Are you interested in furthering Parkinson's science? View PDF's open grant programs.

Learn More


Kinase domain inhibition of leucine rich repeat kinase 2 (LRRK2) using a [1,2,4]triazolo[4,3-b]pyridazine scaffold.

PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research. 

Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members?  Please browse PDF's educational materials and programs - which are all available electronically or in print.  Order for yourself, a loved one or in bulk for your patients or support group.

Bioorg Med Chem Lett 2014 Sep; 24(17):4132-40

Authors: Paul Galatsis, Jaclyn L Henderson, Bethany L Kormos, Seungil Han, Ravi G Kurumbail, Travis T Wager, Patrick R Verhoest, G Stephen Noell, Yi Chen, Elie Needle, Zdenek Berger, Stefanus J Steyn, Christopher Houle, Warren D Hirst

Leucine rich repeat kinase 2 (LRRK2) has been genetically linked to Parkinson's disease (PD). The most common mutant, G2019S, increases kinase activity, thus LRRK2 kinase inhibitors are potentially useful in the treatment of PD. We herein disclose the structure, potential ligand-protein binding interactions, and pharmacological profiling of potent and highly selective kinase inhibitors based on a triazolopyridazine chemical scaffold.

PMID: 25113930 [PubMed - as supplied by publisher]

See More

Back to PubMed Articles